Journal
NATURE REVIEWS NEUROSCIENCE
Volume 14, Issue 2, Pages 128-142Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrn3407
Keywords
-
Categories
Funding
- National Institutes of Health [RO1 NS062002, PO1 NS042345, PO1 NS023393]
Ask authors/readers for more resources
Traumatic brain injury (TBI) is a leading cause of mortality and morbidity both in civilian life and on the battlefield worldwide. Survivors of TBI frequently experience long-term disabling changes in cognition, sensorimotor function and personality. Over the past three decades, animal models have been developed to replicate the various aspects of human TB!, to better understand the underlying pathophysiology and to explore potential treatments. Nevertheless, promising neuroprotective drugs that were identified as being effective in animal TBI models have all failed in Phase II or Phase III clinical trials. This failure in clinical translation of preclinical studies highlights a compelling need to revisit the current status of animal models of TBI and therapeutic strategies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available